20/20 Biolabs is trading 6.05% up at $0.55 amid supportive broader sentiment after softer inflation reduced expectations for a September Federal Reserve rate hike.
- Shares rose 12.49% on August 13 and 5.95% on August 12.
- No fresh company-specific announcement for August 14 was identified; the latest notable updates were an August 5 investor webinar and August 6 commentary on record quarterly cancer-testing revenue.
- Today’s major-index gains are modest.